MA38493A1 - Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane - Google Patents
Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophaneInfo
- Publication number
- MA38493A1 MA38493A1 MA38493A MA38493A MA38493A1 MA 38493 A1 MA38493 A1 MA 38493A1 MA 38493 A MA38493 A MA 38493A MA 38493 A MA38493 A MA 38493A MA 38493 A1 MA38493 A1 MA 38493A1
- Authority
- MA
- Morocco
- Prior art keywords
- tryptophan
- treat
- immunosuppression
- inhibitors
- metabolism
- Prior art date
Links
- 206010062016 Immunosuppression Diseases 0.000 title abstract 4
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 abstract 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des inhibiteurs d'ido et de tdo et des compositions pharmaceutiques les comprenant, qui peuvent être utilisés pour moduler une activité de l'indoleamine 2,3-dioxygénase et de la tryptophane 2,3 dioxygénase ; traiter l'immunosuppression ; traiter des états pathologiques qui sont améliorés par inhibition de la dégradation du tryptophane ; augmenter l'efficacité d'un traitement anticancéreux qui consiste à administrer un agent anticancéreux ; traiter l'immunosuppression spécifique d'une tumeur associée à un cancer ; et traiter l'immunosuppression associée à une maladie infectieuse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784089P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/022680 WO2014159248A1 (fr) | 2013-03-14 | 2014-03-10 | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38493A1 true MA38493A1 (fr) | 2017-02-28 |
| MA38493B1 MA38493B1 (fr) | 2017-10-31 |
Family
ID=50686105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38493A MA38493B1 (fr) | 2013-03-14 | 2014-03-10 | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9617272B2 (fr) |
| EP (2) | EP2976332B1 (fr) |
| JP (2) | JP6093903B2 (fr) |
| KR (1) | KR20150126623A (fr) |
| CN (1) | CN105189466A (fr) |
| AU (2) | AU2014241079C1 (fr) |
| BR (1) | BR112015022588A2 (fr) |
| CA (1) | CA2902174A1 (fr) |
| CL (2) | CL2015002649A1 (fr) |
| CR (1) | CR20150485A (fr) |
| IL (1) | IL241027A0 (fr) |
| MA (1) | MA38493B1 (fr) |
| MX (1) | MX361375B (fr) |
| PE (1) | PE20151593A1 (fr) |
| PH (1) | PH12015501866A1 (fr) |
| RU (1) | RU2667509C2 (fr) |
| SA (1) | SA515361127B1 (fr) |
| SG (2) | SG11201507255QA (fr) |
| UA (1) | UA118103C2 (fr) |
| WO (1) | WO2014159248A1 (fr) |
| ZA (1) | ZA201607948B (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (fr) | 2011-04-15 | 2018-03-17 | ||
| US9604982B2 (en) | 2013-03-14 | 2017-03-28 | Janssen Pharmaceutica Nv | P2X7 modulators |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
| ES2845473T3 (es) | 2013-03-14 | 2021-07-26 | Boehringer Ingelheim Int | (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C |
| CN103570727B (zh) | 2013-11-12 | 2015-08-19 | 复旦大学 | 一种n-苄基色胺酮衍生物及其制备方法和应用 |
| CA2956465A1 (fr) | 2014-09-05 | 2016-03-10 | Merck Patent Gmbh | Composes diaza- et triaza- tricycliques a cyclohexyl-ethyle substitue comme antagonistes de l'indoleamine 2,3-dioxygenase (ido) pour le traitement du cancer |
| EP3511331A1 (fr) | 2014-09-12 | 2019-07-17 | Boehringer Ingelheim International GmbH | Inhibiteurs spirocycliques de la cathepsine c |
| AU2015315693B2 (en) | 2014-09-12 | 2020-01-16 | Janssen Pharmaceutica Nv | P2X7 modulating n-acyl-triazolopyrazines |
| WO2016039977A1 (fr) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | Modulateurs de p2x7 |
| GB201417369D0 (en) * | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| WO2016071293A2 (fr) | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Composé pharmaceutique |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| TWI698435B (zh) | 2015-04-10 | 2020-07-11 | 英屬開曼群島商百濟神州有限公司 | 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶 |
| CN108026098B (zh) | 2015-04-12 | 2019-09-03 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
| CN107849024A (zh) * | 2015-05-15 | 2018-03-27 | 吉利德科学公司 | 具有作为吲哚胺2,3‑二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物 |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| CN105037371A (zh) * | 2015-06-30 | 2015-11-11 | 西华大学 | 一种氘代的吲哚胺-2,3-双加氧酶抑制剂 |
| EP4659747A2 (fr) | 2015-07-24 | 2025-12-10 | Lumos Pharma, Inc. | Sels et promédicaments de 1-méthyl-d-tryptophane |
| CN110072864B (zh) | 2015-12-24 | 2022-05-27 | 基因泰克公司 | Tdo2抑制剂 |
| CN107056785B (zh) * | 2016-01-02 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为ido和tdo抑制剂的杂环化合物 |
| US20190031665A1 (en) * | 2016-02-02 | 2019-01-31 | Emcure Pharmaceuticals Limited | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer |
| EP3418282A4 (fr) * | 2016-02-19 | 2019-01-09 | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. | Composé tricyclique servant d'immunomodulateur |
| TW201736373A (zh) * | 2016-02-19 | 2017-10-16 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | 作為免疫調節劑的三並環化合物 |
| WO2017149469A1 (fr) | 2016-03-03 | 2017-09-08 | Emcure Pharmaceuticals Limited | Composés hétérocycliques utiles en tant que modulateurs de l'ido et/ou de la tdo |
| JP6948345B2 (ja) * | 2016-04-29 | 2021-10-13 | イオメット ファーマ リミテッド | インドールアミン２，３−ジオキシゲナーゼ及び／又はトリプトファン−２，３−ジオキシゲナーゼの阻害薬としての新規置換イミダゾピリジン化合物 |
| CN107383012B (zh) * | 2016-05-16 | 2021-09-28 | 鲁南制药集团股份有限公司 | 含二环的咪唑醇衍生物 |
| WO2017198159A1 (fr) * | 2016-05-16 | 2017-11-23 | 鲁南制药集团股份有限公司 | Dérivé d'imidazole contenant un cycle de liaison |
| CN107663159A (zh) * | 2016-07-29 | 2018-02-06 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| CA3037333A1 (fr) | 2016-09-19 | 2018-03-22 | University Of South Florida | Procede de ciblage de virus oncolytiques aux tumeurs |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| US10882856B2 (en) | 2016-09-24 | 2021-01-05 | Beigene, Ltd. | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases |
| JP7623784B2 (ja) | 2016-10-13 | 2025-01-29 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
| TW201815793A (zh) * | 2016-10-21 | 2018-05-01 | 江蘇恆瑞醫藥股份有限公司 | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 |
| US10604529B2 (en) | 2016-12-20 | 2020-03-31 | Shenzhen Chipscreen Biosciences Co., Ltd. | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| CA3047002A1 (fr) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Nouveaux composes utiles en tant qu'inhibteurs de l'indoleamine 2,3-dioxygenase et/ou du tryptophane dioxygenase |
| EP3645537A1 (fr) | 2017-06-28 | 2020-05-06 | Genentech, Inc. | Inhibiteurs de tdo2 et ido1 |
| WO2019005559A1 (fr) | 2017-06-28 | 2019-01-03 | Genentech, Inc. | Inhibiteurs de tdo2 et ido1 |
| CN109384791B (zh) * | 2017-08-09 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法 |
| CN111051305A (zh) * | 2017-08-22 | 2020-04-21 | 吉利德科学公司 | 治疗性杂环化合物 |
| BR112020005100A2 (pt) * | 2017-09-15 | 2020-09-15 | Taiho Pharmaceutical Co., Ltd. | usos de um composto inibidor de hsp90 para produzir um agente profilático e/ou terapêutico para doenças que envolvem expressão de ido e para produzir uma composição farmacêutica para tratar tumores ido-positivos |
| JP7306634B2 (ja) * | 2017-10-19 | 2023-07-11 | 一般社団法人ファルマバレープロジェクト支援機構 | Ｉｄｏ／ｔｄｏ阻害剤 |
| CN111386114A (zh) | 2017-11-25 | 2020-07-07 | 百济神州有限公司 | 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑 |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| EP3768666A1 (fr) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Composés et procédés de modulation d'ido et de tdo, et indications pour ceux-ci |
| WO2020018670A1 (fr) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Composés utiles en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase et/ou de la tryptophane dioxygénase |
| CN116574105B (zh) * | 2018-09-27 | 2025-10-10 | 深圳微芯生物科技股份有限公司 | 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物 |
| MY205440A (en) | 2018-09-28 | 2024-10-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| KR20210069079A (ko) | 2018-09-28 | 2021-06-10 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제 |
| JP7697934B2 (ja) | 2019-09-30 | 2025-06-24 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射線標識されたｍｇｌ ｐｅｔリガンド |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| EP4052705A1 (fr) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions pour le traitement des maladies ou des pathologies associées à l'ebv |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH516573A (de) * | 1967-08-15 | 1971-12-15 | Sandoz Ag | Verfahren zur Herstellung von 5-Hydroxy-5-phenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindolen |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US6451840B1 (en) | 1997-12-05 | 2002-09-17 | Medical College Of Georgia Research Institute, Inc. | Regulation of T cell-mediated immunity by tryptophan |
| CA2483451C (fr) | 2002-04-12 | 2014-07-29 | Medical College Of Georgia Research Institute, Inc. | Populations de cellules presentatrices de l'antigene et leur utilisation comme reactifs pour renforcer ou diminuer la tolerance immunitaire |
| ES2323952T3 (es) * | 2002-05-15 | 2009-07-28 | Janssen Pharmaceutica Nv | 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg. |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| DE102007020493A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Amid-Derivate |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| CA2722159C (fr) | 2008-04-24 | 2016-04-05 | Newlink Genetics Corporation | Inhibiteurs de l'ido |
| WO2010056567A1 (fr) * | 2008-11-13 | 2010-05-20 | Merck Sharp & Dohme Corp. | Antagonistes imidazoisoindoles des récepteurs du neuropeptide s |
| EP2493862B1 (fr) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Dérivés imidazole comme inhibiteurs de l'ido |
| JP2012037986A (ja) | 2010-08-04 | 2012-02-23 | Canon Inc | 画像形成装置及びその制御方法と画像形成システム |
| NO2694640T3 (fr) | 2011-04-15 | 2018-03-17 |
-
2014
- 2014-03-10 KR KR1020157025259A patent/KR20150126623A/ko not_active Withdrawn
- 2014-03-10 EP EP14722814.2A patent/EP2976332B1/fr not_active Not-in-force
- 2014-03-10 PE PE2015001907A patent/PE20151593A1/es not_active Application Discontinuation
- 2014-03-10 CA CA2902174A patent/CA2902174A1/fr not_active Abandoned
- 2014-03-10 SG SG11201507255QA patent/SG11201507255QA/en unknown
- 2014-03-10 MX MX2015011385A patent/MX361375B/es active IP Right Grant
- 2014-03-10 MA MA38493A patent/MA38493B1/fr unknown
- 2014-03-10 SG SG10201707545XA patent/SG10201707545XA/en unknown
- 2014-03-10 US US14/774,450 patent/US9617272B2/en not_active Expired - Fee Related
- 2014-03-10 CN CN201480015368.3A patent/CN105189466A/zh active Pending
- 2014-03-10 BR BR112015022588A patent/BR112015022588A2/pt not_active Application Discontinuation
- 2014-03-10 AU AU2014241079A patent/AU2014241079C1/en not_active Ceased
- 2014-03-10 JP JP2016501035A patent/JP6093903B2/ja not_active Expired - Fee Related
- 2014-03-10 EP EP18152869.6A patent/EP3366678A1/fr not_active Withdrawn
- 2014-03-10 RU RU2015143990A patent/RU2667509C2/ru not_active IP Right Cessation
- 2014-03-10 WO PCT/US2014/022680 patent/WO2014159248A1/fr not_active Ceased
- 2014-10-03 UA UAA201510014A patent/UA118103C2/uk unknown
-
2015
- 2015-08-25 PH PH12015501866A patent/PH12015501866A1/en unknown
- 2015-09-01 IL IL241027A patent/IL241027A0/en unknown
- 2015-09-11 CL CL2015002649A patent/CL2015002649A1/es unknown
- 2015-09-14 CR CR20150485A patent/CR20150485A/es unknown
- 2015-09-14 SA SA515361127A patent/SA515361127B1/ar unknown
-
2016
- 2016-08-01 CL CL2016001940A patent/CL2016001940A1/es unknown
- 2016-11-14 JP JP2016221202A patent/JP6352368B2/ja not_active Expired - Fee Related
- 2016-11-17 ZA ZA2016/07948A patent/ZA201607948B/en unknown
-
2017
- 2017-02-16 US US15/434,414 patent/US9981973B2/en not_active Expired - Fee Related
- 2017-03-13 AU AU2017201693A patent/AU2017201693A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38493B1 (fr) | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane | |
| EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
| EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
| MA38986B1 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
| EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MA45029B1 (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| MX2013012021A (es) | Derivados de imidazol fusionados utiles como inhibidores de indoleamina 2-3 dioxigenasa (ido). | |
| MA38483A1 (fr) | Inhibiteurs de l'ido | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| EP3524267A4 (fr) | Traitement contre le cancer pharmacorésistant par administration d'un conjugué anticorps anti-her2/médicament | |
| EA201990240A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201790992A1 (ru) | Иммунорегуляторные агенты | |
| AR101177A1 (es) | Inhibidores de la syk | |
| MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| MA48728B1 (fr) | Niraparib, acétate d'abiratérone et prednisone pour le traitement du cancer de la prostate | |
| EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
| EA201101579A1 (ru) | Имидазо[1,2-а]пиридин-2-ил-фенил производные для лечения рака | |
| MX2023009976A (es) | Compuestos de pladienolida y su uso. |